Immune thrombocytopenia
An updated review from etiopathophysiology, laboratory investigations and current therapy
Keywords:
Isolated Thrombocytopenia, Diagnosis, primary, immune-mediatedAbstract
An inherited condition with isolated thrombocytopenia, immune thrombocytopenia (ITP) is still unknown in terms of the cause. A primary or secondary ITP diagnosis is determined by whether or not an underlying treatable cause exists. Diagnosis of primary ITP is based on the exclusion and hence does not have a gold standard test to validate it. Before classifying a patient as primary ITP, recent medication use, infections, lymphoproliferative illnesses, and connective tissue disorders should be checked out. An in-depth look at the most recent developments in ITP diagnostics and treatment is provided in this study. Our research was supported by GOOGLE Scholar, PUBMED, and ClinicalTrial.gov databases. Idiopathic thrombocytopenic purpura was also included in the search, as was "immune-mediated thrombocytopenia," "idiopathic thrombocytopenic purpura," and "isolated thrombocytopenia." It was found that more research is needed to better understand the underlying mechanisms of ITP. For example, corticosteroids have both short- and long-term side effects when used in the first place. In light of this, future research may need a rethinking of ITP treatment recommendations and the use of viable alternative drugs.
Downloads
References
Abe Y, Wada H, Tomatsu H, et al. A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). Thromb Res. 2006;118(4):463–469.
Ahmad Z, Durrani NU, Hazir T. Bone marrow examination in ITP in children: is it mandatory? J Coll Physicians Surg Pak. 2007;17 (6):347–349.
Ahn YS, Rocha R, Mylvaganam R, et al. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med. 1989;111 (9):723–729.
Altintas A, Ozel A, Okur N, et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis. 2007;24(2):163–168.
Ammann EM, Haskins CB, Fillman KM, et al. Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs. Am J Hematol. 2016;91(6):594–605.
Arai Y, Jo T, Matsui H, et al. Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis. Haematologica. 2018;103(1):163–171.
Aramaki M, Matsumoto T, Kitano S. (Laparoscopic and open splenectomy for idiopathic thrombocytopenic purpura). Nihon Rinsho Japan J Clin Med. 2003;61(4):599–603.
Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombo- cytopenic purpura. Blood. 2010;115(1):29–31. .
Audia S, Mahévas M, Samson M, et al. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620–632.
Balduini CL, Pecci A, Savoia A. Recent advances in the understand- ing and management of MYH9-related inherited thrombocytopenias. Br J Haematol. 2011 Jul;154(2):161-174.
Bastida JM, Benito R, Lozano ML, et al. Molecular Diagnosis of Inherited Coagulation and Bleeding Disorders. Semin Thromb Hemost. 2019;45(7):695–707.
Bidika E, Fayyaz H, Salib M, et al. Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment. Cureus. 2020;12(8):e9920.
Bofill Rodriguez M, Lethaby A, Low C, et al. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;8 (8): Cd001016.
Borst F, Keuning JJ, Van Hulsteijn H, et al. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombo- cytopenic purpura in adults. Ann Hematol. 2004;83(12):764–768.
Boruchov DM, Gururangan S, Driscoll MC, et al. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007;110 (10):3526–3531.
Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25(2):52–60.
Buckley L, Guyatt G, Fink HA, et al. American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69 (8):1521–1537. . Hoboken, NJ. 2017
Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phases 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–930.
Bussel JB, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94(5):546–553.
Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–3894.
Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idio- pathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641–648. . London, England
Buzelé R, Barbier L, Sauvanet A, et al. Medical complications follow- ing splenectomy. J Visc Surg. 2016;153(4):277–286.
Chan H, Moore JC, Finch CN, et al. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003;122(5):818–824.
Chang H, Tang TC, Hung YS, et al. Immune thrombocytopenia: effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment. Eur J Haematol. 2018;101(4):549–555.
Chater C, Terriou L, Duhamel A, et al. Reemergence of Splenectomy for ITP Second-line Treatment? Ann Surg. 2016;264(5):772–777.
Chen X, Peng B, Cai Y, et al. Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary? J Surg Res. 2011;170(2):e225–32.
Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402.
Cheng G. Thrombopoietin Receptor Agonists for the treatment of ITP. Japan J Clin Hematol. 2013;54(10):1915–1918.
Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(9):831–836.
Cheung E, Liebman HA. Thyroid disease in patients with immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23 (6):1251–1260.
Choi PY, Roncolato F, Badoux X, et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126(4):500–503.
Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46(1 Suppl 2): S2–14.
Cines DB, Wasser J, Rodeghiero F, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017;102(8):1342–1351.
Colović M, Suvajdzic N, Colović N, et al. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets. 2011;22(2):153–156.
Cooper N, Ghanima W, Solomon CG. Immune Thrombocytopenia. N Engl J Med. 2019;381(10):945–955.
Cooper N. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6):1317–1327.
Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Directions Autoimmunity. 2005;8:140–174.
Deshayes S, Khellaf M, Zarour A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITPritux. Am J Hematol. 2019;94(12):1314–1324.
Długosz-Danecka M, Zdziarska J, Jurczak W. Avatrombopag for the treatment of immune thrombocytopenia. Expert Rev Clin Immunol. 2019;15(4):327–339.
Dou X, Yang R. Current and emerging treatments for immune thrombocytopenia. Expert Rev Hematol. 2019;12(9):723–732.
Duperier T, Brody F, Felsher J, et al. Predictive factors for successful laparoscopic splenectomy in patients with immune thrombocytopenic purpura. Arch Surg. 2004;139(1):61–66. Chicago, Ill: 1960. discussion 6.
Emilia G, Messora C, Longo G, et al. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol. 1996;93(2):341–344.
Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99(4):1482–1485.
Eslick R, McLintock C. Managing ITP and thrombocytopenia in pregnancy. Platelets. 2020;31(3):300–306.
Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176(3):365–394.
Estcourt LJ, Desborough M, Brunskill SJ, et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database Syst Rev. 2016;3(3): Cd009733.
Fabris F, Tassan T, Ramon R, et al. Age as the major predictive factor of long-term response to splenectomy in immune thrombo- cytopenic purpura. Br J Haematol. 2001;112(3):637–640.
Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993;328(17):1226–1229.
Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab. Rev Med Virol. 2019;29(6): e2077.
Fogarty PF, Tarantino MD, Brainsky A, et al. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012;28(1):79–87.
Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. Expert Rev Hematol. 2017;10(1):99–106.
Freiberg A, Mauger D. Efficacy, safety, and dose response of intra- venous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children. Semin Hematol. 1998;35(1 Suppl 1):23–27.
Frydman GH, Davis N, Beck PL, et al. Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: a Review and the Role of Biogeography. Helicobacter. 2015;20(4):239–251.
Gaibullaeva, N. N. (2021). The role of clinical examination early diagnosis of glaucoma. International Journal of Health & Medical Sciences, 4(3), 333-337. https://doi.org/10.31295/ijhms.v4n3.1745
Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95(8):2523–2529.
George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.
Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937–944. .
Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9978):1653–1661.
Gillis S, Dann EJ, Berkman N, et al. Fatal Haemophilus influenzae septicemia following bronchoscopy in a splenectomized patient. Chest. 1993;104(5):1607–1609.
Giordano P, Urbano F, Lassandro G, et al. Role of antithyroid auto-immunity as a predictive biomarker of chronic immune thrombocytopenia. Pediatr Blood Cancer. 2019;66(1):e27452.
Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359(9300):23–29. . London, England
Godeau B, Zini JM, Schaeffer A, et al. High-dose methylprednisolone is an alternative treatment for adults with autoimmune thrombocytopenic purpura refractory to intravenous immunoglobulins and oral corticosteroids. Am J Hematol. 1995;48(4):282–284.
Goel R, Chopra S, Tobian AAR, et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion. 2019;59(1):169–176.
Goel R, Ness PM, Takemoto CM, Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9):1470–1476.
González-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111–116.
Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11):1976–1981. .
Guidry JA, George JN, Vesely SK, et al. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol. 2009;83 (3):175–182.
Guidry JA, Watson S, George JN, et al. Addendum to corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient perspectives. Eur J Haematol. 2009;83(5):497–498.
Hamad H, Sahu KK, Dunn S, et al. Rifampin Induced Thrombotic Thrombocytopenic Purpura. Indian J Hematol Blood Transfus. 2020;36(3):575–577.
Heng LL, Caguioa P, Chin NS, et al. Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region. Int J Hematol. 2011;94(2):142–149.
Hindilerden F, Yönal-Hindilerden İ, Yenerel MN, et al. Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases. Turk J Haematol. 2017;34(1):72–80.
Hong F, Ruiz R, Price H, et al. Safety profile of WinRho anti-D. Semin Hematol. 1998;35(1 Suppl 1):9–13.
Hong J, Bang SM, Mun YC, et al. Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP). J Korean Med Sci. 2018;33(19): e142.
Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353–357.
Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228–1231. . London, England
Ioachimescu AG, Makdissi A, Lichtin A, et al. Thyroid disease in patients with idiopathic thrombocytopenia: a cohort study. Thyroid. 2007;17(11):1137–1142.
Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol. 2016;95(7):1077–1087.
Joo EJ, Chang Y, Yeom JS, et al. B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis. J Viral Hepat. 2017;24(3):253–258.
Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479–490.
Kado R, McCune WJ. Treatment of primary and secondary immune thrombocytopenia. Curr Opin Rheumatol. 2019;31(3):213–222.
Kappers-Klunne MC. Van’t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001;114(1):121–125.
Kashiwagi H, Kuwana M, Hato T, et al. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. Int J Hematol. 2020;111(3):329–351.
Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881–887. .
Khera S, Pramanik SK, Yanamandra U, et al. Dapsone: an Old but Effective Therapy in Pediatric Refractory Immune Thrombocytopenia. Indian J Hematol Blood Transfus. 2020;36(4):690–694.
Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104 (9):2623–2634.
Krause JR. Chronic idiopathic thrombocytopenic purpura (ITP:) development of acute non-lymphocytic leukemia subsequent to treatment with cyclophosphamide. Med Pediatr Oncol. 1982;10 (1):61–65.
Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–423.
Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–1899.
Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci. 2003;28(3):249–255.
Lazarus AH. Mechanism of action of IVIG in ITP. Vox Sang. 2002;83 (Suppl 1):53–55.
Lethaby A, Hussain M, Rishworth JR, et al. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2015;4(6): Cd002126.
Liebman HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. 2009;46(1 Suppl 2): S33–6.
Liu W, Gu X, Fu R, et al. The Effect of Danazol in Primary Immune Thrombocytopenia: an Analysis of a Large Cohort From a Single Center in China. Clin Appl Thromb Hemost. 2016;22(8):727–733.
Marangon M, Vianelli N, Palandri F, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98(4):371–377.
Marta GN, De Campos FP. Immune thrombocytopenia and auto-immune thyroid disease: a controversial overlap. Autops Case Rep. 2015;5(2):45–48.
McCrae KR. Better late than never? Blood. 2013;122(11):1844–1845.
McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol. 2003;25(Suppl 1): S57–61.
McMillan R. Antiplatelet antibodies in chronic immune thrombo- cytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23 (6):1163–1175.
Messer J, Reitman D, Sacks HS, et al. Association of adrenocortical steroid therapy and peptic-ulcer disease. N Engl J Med. 1983;309 (1):21–24.
Mishra K, Jandial A, Malhotra P, et al. Wet purpura: a sinister sign in thrombocytopenia. BMJ Case Rep. 2017 Sep 1;2017.
Mishra K, Jandial A, Sandal R, et al. Poor Platelet Function on Sonoclot Signature Is Associated with High Incidence of Bleeding in Severe Immune Thrombocytopenia. Blood. 2018;132(Supplement 1):4991.
Mishra K, Kumar S, Jandial A, et al. Real-world Experience of Rituximab in Immune Thrombocytopenia. Indian J Hematol Blood Transfus. 2020 (accepted). https://doi.org/10.1007/s12288-020- 01351–3
Mishra K, Malhotra P, Jandial A, et al. Bleeding Risk Assessment By Sonoclot in Severe Immune Thrombocytopenia. Blood. 2017;13 (Supplement 1):2320. hio0
Mishra K, Pramanik S, Jandial A, et al. Real-world experience of eltrombopag in immune thrombocytopenia. Am J Blood Res. 2020;10(5):240–251.
Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016;3(10):e489–e96. .
Miyakawa Y, Katsutani S, Yano T, et al. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombo- cytopenia refractory to conventional therapy. Int J Hematol. 2015;102(6):654–661.
Mizutani H, Furubayashi T, Imai Y, et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW x BXSB) F1. Blood. 1992;79 (4):942–947.
Molinelli E, Paolinelli M, Campanati A, et al. Metabolic, pharmaco- kinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol. 2019;15(5):367–379.
Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol. 2010;150(1):9–20.
Moore DC, Gebru T, Muslimani A. Fostamatinib for the treatment of immune thrombocytopenia in adults. Am J Health-system Pharm. 2019;76(11):789–794.
Moulis G, Comont T, Germain J, et al. Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry. Blood Adv. 2020;4(9):1974–1977.
Naithani R, Kumar R, Mahapatra M, et al. Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia. Platelets. 2009;20(7):525–527.
Nampoothiri RV, Singh C, Mishra K, et al. Immune thrombocytopenia is the commonest diagnosis on consultative hematology - a single centre experience. Indian J Hematol Blood Transfus. 2017 Nov; 33(Suppl 1): S104
Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946–1953. .
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207.
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866.
Neunert CE, Cooper N. Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematol Am Soc Hematol Educ Program. 2018;2018(1):568–575.
Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombo poiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006;135(4):547–553.
Newland A, Lee EJ, McDonald V, et al. Fostamatinib for persistent/ chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9–25.
Neylon AJ, Saunders PW, Howard MR, et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122(6):966–974.
Niscola P, Scaramucci L, Giovannini M. Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia. Immunotherapy. 2018;10(1):5–7.
Ojima H, Kato T, Araki K, et al. Factors predicting long-term responses to splenectomy in patients with idiopathic thrombocytopenic purpura. World J Surg. 2006;30(4):553–559.
Park YH, Yi HG, Kim CS, et al. Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: a Multicenter Retrospective Study. Acta Haematol. 2016;135(3):162–171. .
Park YH, Yi HG, Lee MH, et al. Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study. Int J Hematol. 2016;103(2):180–188.
Pasa S, Altintas A, Cil T, et al. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocytopenic purpura. J Thromb Thrombolysis. 2009;27(3):329–333.
Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms, and predictors. Expert Rev Clin Immunol. 2019;15(4):383–389.
Phillips M. Danazol and idiopathic thrombocytopenic purpura. Ann Intern Med. 1990;112(6):474–475.
Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, et al. Antiphospholipid antibodies in adults with immune thrombocyto- penic purpura. Br J Haematol. 2008;142(4):638–643.
Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817.
Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186. .
Puavilai T, Thadanipon K, Rattanasiri S, et al. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. Br J Haematol. 2020;188(3):450–459.
Qu M, Zhou J, Yang SJ, et al. Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis. J Int Med Res. 2020;48(10):300060520962348.
Rattanathammethee T, Theerajangkhaphichai W, Rattarittamrong E, et al. The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia. Hematol Rep. 2017;9 (1):7034.
Reid DM, Shulman NR. Pulse cyclophosphamide to treat idiopathic thrombocytopenic purpura. Blood. 1995;86(1):414–415.
Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351–358.
Ren DQ, Gao H, Li ZC. (Prognostic significance of peripheral blood cell and bone marrow megakaryocyte counts in patients with idiopathic thrombocytopenic purpura). Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11(2):199–201.
Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013;121(14):2596–2606. .
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombo- cytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393.
Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol. 2018;181(2):183–195.
Sahu KK, Jindal V, Anderson J, et al. Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia. J Blood Med. 2020;11:267–277.
Sahu KK, Lal A, Mishra AK, et al. Methemoglobinemia in Transplant Recipient Patients: future of Dapsone as Pneumocystis carinii Pneumonia Prophylaxis. Prog Trans. 2020;30(1):71–72. . Aliso Viejo, Calif
Sahu KK, Petrou N, Cohn Z, et al. Rituximab-induced late-onset neutropenia. BMJ Case Rep. 2019;12(12):12.
Sahu KK, Prakash G, Khadwal A, et al. Case of Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplant Patient. Indian J Hematol Blood Transfus. 2016;32(Suppl 1):196–200.
Salama A, Kiefel V, Amberg R, et al. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D). Blut. 1984;49(1):29–35.
Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121 (3):537–545.
Salib M, Clayden R, Clare R, et al. Difficulties in establishing the diagnosis of immune thrombocytopenia: an agreement study. Am J Hematol. 2016;91(8): E327–9.
Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89(8):2689–2700. .
Schiavotto C, Castaman G, Rodeghiero F. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. Haematologica. 1993;78(6 Suppl 2):29–34.
Sheema K, Ikramdin U, Arshi N, et al. Role of Helicobacter pylori Eradication Therapy on Platelet Recovery in Chronic Immune Thrombocytopenic Purpura. Gastroenterol Res Pract. 2017; 2017:9529752.
Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol. 2011;94(1):71–80.
Shvidel L, Sigler E, Shtalrid M, et al. Vincristine-loaded platelet infusion for the treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: rethinking old cures. Am J Hematol. 2006;81(6):423–425.
Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. mAbs. 2018;10 (7):1111–1130.
Sotomayor-Ramírez RK. Efficacy and safety of laparoscopic splenectomy: a review of 14 adult cases using the lateral approach. Boletin de la Asociacion Medica de Puerto Rico. 2009;101(2):43–49.
Sperati CJ, Streiff MB. Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag. Am J Hematol. 2010;85(9):724–726.
Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88 (7):1351–1389.
Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98(5):436–442.
Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84(12):4203–4208.
Stirnemann J, Kaddouri N, Khellaf M, et al. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2016;96(3):269–275.
Sultan S, Ahmed SI, Murad S, et al. Primary versus secondary immune thrombocytopenia in adults; a comparative analysis of clinical and laboratory attributes in newly diagnosed patients in Southern Pakistan. Med J Malaysia. 2016;71(5):269–274.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949
Sys J, Provan D, Schauwvlieghe A, et al. The role of splenectomy in autoimmune hematological disorders: outdated or still worth considering? Blood Rev. 2017;31(3):159–172.
Tada K, Ohta M, Saga K, et al. Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. Surg Today. 2018;48(2):180–185. .
Tang YT, He P, Li YZ, et al. Diagnostic value of platelet indices and bone marrow megakaryocytic parameters in immune thrombocytopenic purpura. Blood Coagul Fibrin. 2017;28(1):83–90. .
Taylor A, Neave L, Solanki S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171 (4):625–630.
Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10(5):799–806.
Tran H, Brighton T, Grigg A, et al. A multi-center, single-arm, open-label study evaluating the safety and efficacy of fixed-dose rituximab in patients with refractory, relapsed, or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). Br J Haematol. 2014;167(2):243–251.
Tseng V, Morgan AS, Leith CP, et al. Efficient assessment of peripheral blood lymphocytosis in adults: developing new thresholds for blood smear review by pathologists. Clin Chem Lab Med. 2014;52 (12):1763–1770.
Vancine Califani SM, De Paula EV, Ozelo MC, et al. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets. 2008;19(7):489–495.
Varma S, Kumar S, Garg A, et al. Hepatitis C virus infection among patients with chronic immune thrombocytopenic purpura in the northern India. J Clin Exp Hepatol. 2011;1(2):68–72.
Verlin M, Laros RK Jr., Penner JA. Treatment of refractory thrombo- cytopenic purpura with cyclophosphamine. Am J Hematol. 1976;1 (1):97–104.
Vianelli N, Galli M, De Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005;90(1):72–77.
Wardrop D, Estcourt LJ, Brunskill SJ, et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with hematological disorders. Cochrane Database Syst Rev. 2013;(7): Cd009733. DOI:10.1002/14651858.CD009733.pub2.
Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol. 1998;35(1 Suppl 1):14–22.
Wongrakpanich S, Salahuddin M, Mittar P. An abnormal peripheral blood smear and altered mental status. Cleve Clin J Med. 2016;83 (9):643–644.
Wu JM, Lai IR, Yuan RH, et al. Laparoscopic splenectomy for idio- pathic thrombocytopenic purpura. Am J Surg. 2004;187(6):720–723.
Xu H, Cai R. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Expert Rev Clin Pharmacol. 2019;12(9):859–865.
Yang YJ, Yun GW, Song IC, et al. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med. 2011;26(4):449–454.
Yenson PR, Forrest D, Schmiegelow K, et al. Azathioprine- associated acute myeloid leukemia in a patient with Crohn’s disease and thiopurine S-methyltransferase deficiency. Am J Hematol. 2008;83(1):80–83.
Yuan YP, Yang X, Chen YJ. Research Advances on the Pathogenesis of Primary Immune Thrombocytopenia–Review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019;27(5):1706–1710.
Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14):2755–2762. .
Zaja F, Barcellini W, Cantoni S, et al. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Am J Hematol. 2016;91(5): E293–5.
Zaja F, Marin L, Chiozzotto M, et al. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol. 2012;87(3):321–323.
Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329–334.
Zhang MK, Xu TQ, Zhang XJ, et al. Thrombocytopenia in 737 adult intensive care unit patients: a real-world study of associated factors, drugs, platelet transfusion, and clinical outcome. SAGE Open Med. 2020;8:2050312120958908.
Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–1547.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
